EKF DIAGNOSTICS HOLDINGS PLC — M&A Activity 2018

Nov 1, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1097G

EKF Diagnostics Holdings PLC

01 November 2018

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Update regarding AIM admission of RenalytixAI and planned change of EKF's nominated adviser

EKF Diagnostics Holdings plc (AIM: EKF) announces that, further to the announcement on 31 October confirming that Renalytix AI plc ("RenalytixAI") had successfully raised £22.25 million in gross proceeds, RenalytixAI will now be admitted to trading on AIM on 6 November 2018. An updated Schedule One announcement is expected to be issued on 2 November 2018.

Participants in the fundraising will be contacted by N+1 Singer, the Company or Link Asset Services to confirm updated settlement instructions.

EKF and N+1 Singer, the Company's current nominated adviser and broker, have agreed that in order to preserve the independence of its nominated adviser, EKF will appoint a new nominated adviser after the admission of RenalytixAI.  A further announcement will be made in this regard in due course. 

N+1 Singer will continue to act as broker to EKF.

Enquiries: EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman		Tel: 029 2071 0570
Julian Baines, CEO Richard Evans, FD & COO
N+1 Singer (Nominated Adviser & Broker)		Tel: 020 7496 3000
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking)
Walbrook PR Limited	Tel: 020 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne		Mob: 07980 541 893 / 07584 391 303

About EKF Diagnostics Holdings plc                                                                           www.ekfdiagnostics.com

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDDFLFBVFFLFBD